Related Experiment Video

Updated: Jul 19, 2026

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent
06:54

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent

Published on: September 3, 2013

11.2K

Prostate-Specific Membrane Antigen: Gateway to Management of Advanced Prostate Cancer.

Lena M Unterrainer1,2, Jeremie Calais1, Neil H Bander3,4

  • 1Ahmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California, USA; email: lunterrainer@mednet.ucla.edu, jcalais@mednet.ucla.edu.

Annual Review of Medicine
|January 29, 2024
PubMed
Summary

Prostate-specific membrane antigen (PSMA)-targeted therapies and imaging, particularly using radioligands, show significant promise for advanced prostate cancer (PC). PSMA-targeted radioligand therapy offers improved outcomes and quality of life for patients with metastatic castration-resistant PC.

Keywords:
PETPSMA imagingantibody therapypositron emission tomographyprecision oncologyprostate cancerprostate-specific membrane antigenradioligand therapy

More Related Videos

A Murine Orthotopic Bladder Tumor Model and Tumor Detection System06:23

A Murine Orthotopic Bladder Tumor Model and Tumor Detection System

Published on: January 12, 2017

14.8K
A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

13.1K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...